AstraZeneca, Daiichi Breast-Cancer Drug Gets Nod in England After U.S. Pharma Deal
By Adria Calatayud
AstraZeneca and Daiichi Sankyo's breast-cancer drug Enhertu won approval from the drug-cost watchdog for routine use in England, after the regulator changed its recommendation following the U.S.-U.K. pharmaceutical-pricing deal.
The National Institute for Health and Care Excellence said Thursday that it would recommend Enhertu for routine use on England's National Health Service, which means around 1,000 patients annually with an advanced form of breast cancer can now be offered the treatment.
An independent NICE committee had previously rejected the drug at the price proposed by the companies. The parties reached an agreement after the regulator's methods changed due to the U.S.-U.K. pharma deal, NICE said.
AstraZeneca's U.K. president Tom Keith-Roach said the green light in England brings access to the medicine into line with Scotland and 26 other European countries.
NICE said it had made 25 other breast-cancer treatments available on the NHS since 2018, but that Enhertu for this group of patients was the only one it had been unable to recommend.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
September 17, 2026 02:23 ET (06:23 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States